Humana Q2 2026 Earnings Insight Report
This Humana Q2 2026 earnings report is a HealthWorks AI breakdown of Humana Inc.'s Q2 2026 earnings call and results, covering GAAP and Adjusted EPS, Insurance segment benefit ratio, and Medicare Advantage growth guidance.
Section 1
Executive summary: Humana Q2 2026 earnings takeaways
Humana beat Q2 2026 estimates on both bases against last year's actuals: GAAP diluted EPS of $5.73 versus $4.51 in Q2 2025, Adjusted EPS of $7.61 versus $6.27, and the Insurance segment benefit ratio landed at 91.2%, exactly in line with management's own ‘slightly above 91 percent’ guidance. Shares fell anyway, down about 2.24% in premarket trading. Two things explain why. First, full-year GAAP EPS guidance was cut for the second consecutive quarter, now ‘at least $6.52,’ down from ‘at least $8.36’ set in April and ‘at least $8.89’ set in February, a 27% reduction from where the year started. Second, the cushion that has softened recent quarters is thinning: favorable prior-period claims reserve development came in at $53 million this quarter versus $161 million a year ago.
None of this changes the broader, already-known story. Full-year 2026 Adjusted EPS guidance has held at ‘at least $9.00’ all year, but that number is itself roughly half of 2025's actual $17.14, a decline management has attributed since February to the Bonus Year 2026 Star Ratings revenue headwind, not to anything new this quarter. What is moving is the GAAP side and the composition underneath Adjusted EPS: value creation initiative charges and non-cash valuation items tied to Humana's primary care joint venture are absorbing a larger share of earnings than a year ago. Individual Medicare Advantage membership is tracking toward its reaffirmed ~25% full-year growth guide (6.45 million members at quarter-end, up from 5.23 million a year ago), and CenterWell Senior Primary Care grew patients 27% year to date.
The Star Ratings recovery itself looks real, even if 2026 is still absorbing the cost of the prior decline. Management reported improvement in internally tracked Stars-related measures, with many improving faster than their historical rate of change.
Meanwhile Humana continues to expand rather than retrench, winning a statewide Illinois Medicaid contract as the only new entrant among six awardees, even as it plans for roughly 600,000 of its own MA members to be displaced by its own 2027 plan exits. See the full scorecard in Section 2, and the client-facing implications in Section 7.
Section 2
Did they deliver on what they promised last quarter?
Measured against Humana's own stated commitments from its Q1 2026 and Q4 2025 earnings calls, since this is HealthWorksAI's first Humana Earnings Insight report.
| What they promised in Q1 2026 | What actually happened in Q2 2026 | Verdict |
|---|---|---|
| 2Q26 Insurance segment benefit ratio guided at ‘slightly above 91 percent,’ set on the Q1 2026 call. | Landed at 91.2%, exactly in line with guidance. | Delivered |
| Full-year 2026 Insurance segment benefit ratio guided at 92.75%, plus or minus 25 basis points. | Reaffirmed unchanged on the Q2 call. | On track |
| Full-year 2026 Adjusted EPS guided at ‘at least $9.00,’ set in February and reaffirmed on the Q1 call. | Reaffirmed unchanged again, still ‘at least $9.00.’ | On track |
| Full-year 2026 GAAP EPS guided at ‘at least $8.36’ on the Q1 call, already cut once from February's original ‘at least $8.89.’ | Cut again, to ‘at least $6.52,’ the second consecutive reduction, now 27% below where the year started. | Off track |
| Full-year 2026 individual Medicare Advantage membership growth guided at ‘approximately 25 percent’ over 2025. | Reaffirmed unchanged; actual growth at quarter-end running at 23.4% year over year (6.45 million vs. 5.23 million members). | On track |
| Medical and pharmacy cost trend guided ‘in line with expectations’ for both new and existing members, in the 7%-8% range. | Reaffirmed in line again on the Q2 call. | Delivered |
Section 3
What's actually changing
Full-year 2026 Adjusted EPS guidance: Humana has held its adjusted EPS guidance at ‘at least $9.00’ all year, but that number is itself roughly half of 2025's actual $17.14, guided since February as the price of the Bonus Year 2026 Star Ratings headwind. Nothing about that story is new this quarter.
GAAP EPS guidance: Further, GAAP EPS guidance has now been cut twice in six months, from ‘at least $8.89’ in February to ‘at least $8.36’ in April to ‘at least $6.52’ this quarter, driven by rising value creation initiative and non-cash valuation charges, not by weaker underlying insurance economics.
Star Ratings recovery is tracking ahead of pace on Humana's own numbers: The firm has outpaced its own numbers, clocking historical CAGR across 11 of 12 measured categories. The company is positioned for its 2028 top-quartile and 3%-plus margin commitments, though CMS's next actual ratings release is the real test.
Reserve development is a genuinely thinner cushion this year: $53 million favorable in Q2 2026 versus $161 million in Q2 2025, a real, quantified year-over-year decline consistent with management's own guidance for lower favorable prior-period development in 2026.
Growth and expansion continue on multiple fronts even as margin absorbs pressure: Individual MA membership tracking toward its ~25% full-year growth guide, CenterWell Senior Primary Care up 27% year to date, and a new statewide Illinois Medicaid win; Humana was the only new entrant chosen alongside five incumbents.
Section 4
Key leadership quotes
All quotes below are verbatim from the Q2 2026 earnings call transcript.
“The first half of the year went well, and we're right where we said we'd be at Investor Day last year.”
What this really means: management is framing this quarter as ‘on plan,’ not a surprise beat, consistent with a Star Ratings headwind that was already fully guided back in February.
“Our number one priority in MA bids was to make the necessary margin progression to remain on track to deliver our 2028 commitment of returning to a sustainable margin of at least 3%.”
What this really means: Humana is explicitly prioritizing pricing discipline over enrollment volume in its own bid process, a specific, named margin target the company is holding itself to publicly, three years out.
“Our rate of improvement outpaced, and in many places meaningfully outpaced, the historical CAGR across 11 of the 12 measures.”
What this really means: a specific, quantified claim, 11 of 12 measures, rather than a vague ‘we're improving,’ worth holding management to once CMS actually publishes updated Star Ratings.
“For 2027, we anticipate these plan exits will impact approximately 600,000 members, though we will work to recapture a significant portion of that volume as we did in 2025.”
What this really means: Humana is telling investors, in its own words, that roughly 600,000 of its own members are set to become contestable membership for competitors next AEP, a real, quantified number, not a vague risk disclosure.
“Our 2Q consolidated operating cost ratio is down 120 basis points year-over-year, and we continue to expect a full year reduction of approximately 150 basis points.”
What this really means: efficiency gains, not benefit richness, are carrying the cost ratio improvement this year, worth checking whether that pace holds once the value creation program's own charges roll off.
“We're not going to comment speculatively on the litigation itself…we don't feel that speculating on that does much for anybody.”
What this really means: management is deliberately not connecting current commentary to the ongoing Star Ratings lawsuit, Humana's 2025 challenge was rejected by the court in October 2025 and is under appeal, a real, live legal risk this report's scorecard and guidance numbers don't currently price in.
Section 5
Where the guidance goes from here
Section 6
How the competitive picture is shifting
- Humana is holding to aggressive individual MA growth (~25% guided) at the same time UnitedHealth and Elevance have both signaled margin-over-membership discipline this earnings season, an outlier growth posture worth watching if your plan competes with Humana for the same members.
- The Illinois Medicaid win, the only new entrant chosen alongside five incumbents, shows continued Medicaid appetite even as some national payers have pulled back or flagged Medicaid margin pressure this season.
- Humana's own ~600,000-member 2027 plan-exit exposure is a real, named pool of contestable membership, the same dynamic driving this quarter's competitive-intelligence conversations around United's and CVS's service area reductions.
Section 7
What this means for your plan
If you compete with Humana in individual MA
Expect continued aggressive growth (~25% guided, already running near 23% year over year at Q2) even as some national peers protect margin over volume. The competitive intensity in overlapping markets may not be cooling the way broader industry commentary suggests.
If you're benchmarking your own Star Ratings recovery
Humana's own claimed pace, outpacing historical CAGR across 11 of 12 measures, is a real, quantified benchmark for how fast a Stars turnaround can move once a plan commits resources to it, worth comparing against your own trajectory.
If you have overlapping service areas with Humana
Humana itself is planning for roughly 600,000 of its own members to be displaced by its own 2027 plan exits and says it will only recapture a ‘significant portion.’ The rest becomes exactly the kind of open, contestable membership your own AEP strategy should be positioned to compete for.
If you're weighing how to message GAAP-versus-Adjusted guidance internally or to your board
Humana's widening gap, two consecutive GAAP guidance cuts against an unchanged Adjusted number, is a live example of how that story reads externally, worth considering before your own plan's guidance diverges the same way.
Client-specific implications: No account-specific overlap with Humana's individual MA growth markets or its Illinois Medicaid award could be independently verified for this report. If your book has direct membership exposure in states where Humana is aggressively growing individual MA, or in Illinois ahead of Humana's January 2027 Medicaid go-live, that is worth a direct account-level check rather than assuming from this report alone.
How our clients can use HealthWorksAI to act on this
This is exactly the kind of membership-in-motion story our platform is built to quantify before it shows up in enrollment reports. Clients can run SAE/SAR analysis to see which counties are driving Humana's individual MA growth and whether that growth is coming at your own plan's expense, use disruption analysis to model the roughly 600,000 members Humana itself expects to lose to 2027 plan exits, pressure-test enrollment predictions against Humana's reaffirmed ~25% growth guide, and pull a market snapshot ahead of Humana's Illinois Medicaid go-live in January 2027. Reach out to your Client Success Manager to run this analysis for your own markets.
Section 8
What to watch next quarter
| Star Ratings release | CMS's next published Star Ratings release, expected around October 2026: does Humana's claimed 11-of-12 measure improvement show up in actual bonus-year ratings, the real test behind the 2028 top-quartile commitment. |
| Q3 2026 earnings | Q3 2026 earnings call, expected late October or early November 2026: does GAAP EPS guidance get cut a third consecutive time, or stabilize at ‘at least $6.52.’ |
| AEP 2027 | AEP 2027, October through December 2026: how much of the ~600,000 members Humana expects to lose from its own 2027 plan exits actually gets recaptured versus lost to competitors. |
| Illinois Medicaid | Illinois Medicaid managed care go-live, January 2027: Humana's first entry as a new statewide entrant alongside five incumbents. |
| Litigation appeal | The ongoing Star Ratings litigation appeal: Humana's challenge to its 2025 Star Ratings was rejected by the court in October 2025 and is under appeal. Management is explicitly declining to comment, worth tracking independently rather than waiting for Humana to raise it. |
Sourcing note: this Humana Q2 2026 earnings report draws financial figures from Humana Inc.'s official Q2 2026 earnings release (July 29, 2026) and non-GAAP reconciliation tables. All leadership quotations are verbatim from the full Q2 2026 earnings call transcript (Investing.com, call held July 29, 2026), read directly from the transcript and independently cross-checked, including confirming CFO Celeste Mellet's name and title against Humana's own investor relations records, rather than taken from a single source's summarized excerpt. Prior-quarter commitments referenced in the scorecard are drawn from Humana's own Q1 2026 earnings release and call transcript (April 29, 2026) and Q4 2025 earnings release (February 11, 2026), since this is HealthWorksAI's first Humana Earnings Insight report and no prior HealthWorksAI report exists to benchmark against. This report has not yet undergone HealthWorksAI analyst review; figures and attributions should be verified before external use.
Want this report as a PDF?
Download the full Humana Inc. Q2 2026 Earnings Insight report to save, print, or share with your team.
Download PDF
